Introduction {#sec001}
============

Leishmaniasis is a diverse spectrum of clinical syndromes caused by more than 20 species of the obligate intracellular protozoa parasites of the genus *Leishmania* and is transmitted by the bite of an infected female sand fly. Leishmaniasis is one of the most neglected and poverty-related tropical diseases in the world \[[@pntd.0007698.ref001]\]. The disease is endemic in 98 countries, affecting 12 million people worldwide, with an estimated 350 million people at risk of infection \[[@pntd.0007698.ref002]\]. Unfortunately, in most countries, the incidence of disease is often underestimated largely due to unrecognized cases, lack of access to healthcare, or under-reporting \[[@pntd.0007698.ref003]\]. Different species of *Leishmania* cause disease in both humans and animals, and *Leishmania* is often referred to as a zoonosis. After deposition into the skin, *Leishmania* can give rise to mild and atypical types of cutaneous leishmaniasis (CL), a destructive mucocutaneous leishmaniasis (MCL), and deadly systemic visceral leishmaniasis (VL). The clinical manifestations of disease are largely associated with the infecting strain of the parasite. Considering leishmaniasis is an emerging and uncontrolled disease in some regions and is increasing in some endemic areas, timely diagnosis and treatment of patients is of paramount importance to contain the disease.

Currently available diagnostic tools for leishmaniasis can be divided into three groups: parasitological, serological, and molecular diagnostics, each of them coming with advantages and disadvantages. The traditional parasitological methods, which include microscopy and parasite culturing, remain the diagnostic gold standard. Though technically specific, it suffers from low sensitivity, and only a handful of health centers in the field are able to culture parasites. Serological methods with comparable sensitivity to parasitological methods are available in the form of enzyme-linked immunosorbent assay (ELISA) and rapid diagnostic tests (RDTs) based on rK39 \[[@pntd.0007698.ref004], [@pntd.0007698.ref005]\], immunofluorescence antibody test (IFAT), western blotting, and direct agglutination test (DAT) \[[@pntd.0007698.ref006], [@pntd.0007698.ref007]\]. However, serology-based diagnostic techniques also have some disadvantages, such as cross-reactivity and false-positive results \[[@pntd.0007698.ref004], [@pntd.0007698.ref006], [@pntd.0007698.ref007]\]. Molecular methods provide an effective alternative to the aforementioned methods and are of greater sensitivity and specificity \[[@pntd.0007698.ref006], [@pntd.0007698.ref007]\]. The presence of *Leishmania* DNA as a molecular biomarker for infection can be effectively employed in both human and other mammalian hosts. Human clinical samples, such as whole blood, urine, bone marrow, lymph nodes, serum, buffy coat \[[@pntd.0007698.ref006]\], and cutaneous lesion aspirates or scrapings \[[@pntd.0007698.ref008], [@pntd.0007698.ref009]\], have reliably been used to detect the presence of parasitic DNA. Despite the apparent availability of effective diagnostics tests, resource limitations in endemic countries or a lack of experience among physicians and laboratory technicians in nonendemic countries leads to either no diagnosis or delays and inaccurate diagnosis. Consequently, a sensitive and specific molecular diagnostic method is required in both endemic and nonendemic regions. One of the most basic and widely used molecular diagnostic techniques is polymerase chain reaction (PCR) detection of *Leishmania* DNA \[[@pntd.0007698.ref006], [@pntd.0007698.ref007]\]. Detection of pathogen DNA directly from clinical samples has permitted more analytically sensitive diagnosis of infection. However, the technique requires expensive equipment, DNA purification, a long time to diagnosis, and a lack of field applicability, thereby preventing the use of PCR-based diagnostics in resource-limited, disease-endemic settings. To overcome PCR limitations, in the year 2000, a novel molecular technique, the loop-mediated isothermal amplification (LAMP), was developed as a field-friendly and cost-effective diagnostic tool \[[@pntd.0007698.ref010]\], and it appears to be a feasible molecular diagnostic tool for both endemic and nonendemic regions. LAMP has the advantage of no major capital equipment requirement, simplified DNA extraction methods like boil and spin, naked eye detection of amplification, and the use of dry reagents, including the polymerase enzyme.

Several studies have shown the utility of the LAMP technique as a useful tool for rapid detection of pathogenic agents (bacteria, parasites, and viruses) of infectious diseases \[[@pntd.0007698.ref009], [@pntd.0007698.ref011]--[@pntd.0007698.ref015]\]. LAMP diagnostic kits have also been developed by the Eiken Chemical Co. (Japan) for human African trypanosomiasis (HAT) \[[@pntd.0007698.ref016]\], tuberculosis \[[@pntd.0007698.ref017]\], malaria \[[@pntd.0007698.ref018], [@pntd.0007698.ref019]\], and leishmaniasis \[[@pntd.0007698.ref020], [@pntd.0007698.ref021]\]; and recently the LAMP diagnostic kit for tuberculosis has been endorsed by the World Health Organization \[[@pntd.0007698.ref022]\]. Meridian Biosciences (Cincinnati, OH) has also developed a centrifugation-free assay called *illumi*gene for malaria genus-level detection \[[@pntd.0007698.ref023]\]. Since the advent of LAMP as a simple and robust nucleic acid amplification test (NAAT), different studies have shown a number of prototype LAMP assays in the field of leishmaniasis. Here we present a review, current status, diagnostic performance, and perspectives of molecular-based LAMP technique for leishmaniasis, as well as its prospects as a xenomonitoring/surveillance tool in endemic areas. [Box 1](#pntd.0007698.box001){ref-type="boxed-text"} shows the search strategy and selection criteria used in this review. The flow of included studies is graphically presented in [Fig 1](#pntd.0007698.g001){ref-type="fig"}.

Box 1. Information sources, search strategies, and study selection. {#sec002}
-------------------------------------------------------------------

We searched for articles in PubMed, Embase, Web of Science, Google Scholar, and Scopus, with the following keywords: *Leishmania* LAMP assay; cutaneous leishmaniasis; molecular diagnosis; PCR and LAMP; *Leishmania* diagnosis; colorimetric dye; parasitic DNA; leishmaniasis; mucocutaneous leishmaniasis; visceral leishmaniasis; post kala-azar dermal leishmaniasis; canine leishmaniasis; and sand fly, surveillance, xenomonitoring, and other related words.

The eligibility criteria included the following: original studies evaluating LAMP test; clinical cutaneous leishmaniasis, visceral leishmaniasis, post kala-azar dermal leishmaniasis in human, canine leishmaniasis, and *Leishmania* detection in sand flies as respective target conditions; adequate reference classification; and absolute numbers of true-positive, true-negative, false-positive, and false-negative observations derivable from the data presented in the diagnosis of human leishmaniasis. Commercial and laboratory developed tests were eligible. LAMP test accuracy were summarized as sensitivity and specificity with 95% confidence intervals. Analysis was performed using *Review Manager* (*RevMan*) *Version 5*.*3*. *Copenhagen*: *The Nordic Cochrane Centre*, *The Cochrane Collaboration*, *2014*.

![Flowchart of the studies identified, screened, and included in this review.](pntd.0007698.g001){#pntd.0007698.g001}

LAMP technique: Its developments and features {#sec003}
=============================================

A recent advance in molecular (nucleic acid-based) diagnostics has been the development of LAMP \[[@pntd.0007698.ref010]\], among others like nucleic acid sequence-based amplification (NASBA) and recombinase polymerase amplification (RPA) \[[@pntd.0007698.ref024], [@pntd.0007698.ref025]\]. The LAMP technique employs a *Bacillus stearothermophilus* (*Bst*) DNA polymerase---which has both polymerase and reverse transcriptase activity---and a set of four primers (two inner primers, with typical length of approximately 40--42 bp and two outer primers, with typical length approximately 17--20 bp) that recognize six distinct sequences of the target DNA, which makes them highly specific to the target. Occasionally, the addition of two extra primers (loop forward primer and loop backward primer, with a typical length of approximately 20 bp) referred to as loop primers accelerates the amplification reaction, thereby decreasing the reaction time required \[[@pntd.0007698.ref026]\]. The design of the LAMP primers is easy and can readily be done through a user-friendly online platform: Primer Explorer V4 software (<http://primerexplorer.jp/e>) running in java Runtime environment, a product of Eiken Chemical Co. LAMP has the capacity to amplify a few copies of DNA to 10^9^ in \<60 min with high efficiency \[[@pntd.0007698.ref010]\]. The mechanism behind the LAMP reaction involves three major steps: initiation, cycling amplification, and elongation ([Fig 2](#pntd.0007698.g002){ref-type="fig"}). Typically, the reaction begins with the binding of the inner primers containing sequences of the sense and antisense strands of the target DNA, and this is followed by strand displacement DNA synthesis by the outer primers (initial step). Subsequently, the cyclical amplification step and elongation occur \[[@pntd.0007698.ref010]\]. One good feature of LAMP is the auto strand displacement properties of *Bst* polymerase, which enables amplification reaction using heating block or normal water bath maintained at a specific temperature without the use of expensive thermal cyclers. The appearance of magnesium pyrophosphate precipitate (a by-product of DNA amplification) provides a positive indicator of the target DNA amplification. Real-time turbidimetry facilitates the quantification of the template DNA in the reaction and allows the analysis of minute quantities of DNA. Furthermore, LAMP amplicon can be analyzed using agarose gel electrophoresis and/or simple colorimetric naked eye visualization closed detection systems \[[@pntd.0007698.ref027]\] and real-time fluorimetry \[[@pntd.0007698.ref021], [@pntd.0007698.ref028]\]. Therefore, the major advantage of LAMP is its application in a field or resource-limited setting.

![Schematic representation of molecular mechanism of LAMP (three major steps in the LAMP reaction) and localization of the LAMP primers on target DNA sequence.](pntd.0007698.g002){#pntd.0007698.g002}

Application of LAMP technique to leishmaniasis {#sec004}
==============================================

CL {#sec005}
--

CL is the most prevalent clinical form of leishmaniasis worldwide, characterized by the presence of ulcerative lesions leading to disfiguring and/or incapacitating scars \[[@pntd.0007698.ref002]\]. CL is endemic in the tropics and neotropics and in more than 70 countries worldwide, and 90% of cases occur in seven countries: Afghanistan, Algeria, Brazil, Iran, Peru, Saudi Arabia, and Syria \[[@pntd.0007698.ref029]\]. CL is most commonly associated with *Leishmania* (*Leishmania*) *major*, *L*. (*L*.) *tropica*, and *L*. (*L*.) *aethiopica* species in the Old World and multiple species of *Leishmania*---*L*. (*L*.) *mexicana*, *L*. (*L*.) *amazonensis*, *L*. (*Viannia*) *braziliensis*, *L*. (*V*.) *guyanensis*, *L*. (*V*.) *panamensis*, and *L*. (*V*.) *peruviana*---in the New World \[[@pntd.0007698.ref030]\]. In some regions, two or more species are often sympatric \[[@pntd.0007698.ref031]\]. Species prevalent in the Old World in most cases cause self-limiting ulcers, while the New World species are known to cause a syndrome called American tegumentary leishmaniasis---comprised of CL and a variety of other manifestations, like MCL---and a diffuse and disseminated cutaneous leishmaniasis (DCL or diffuse-CL) \[[@pntd.0007698.ref032]\].

Because the clinical spectrum of CL is broad and can be misdiagnosed as other skin conditions such as cutaneous mycoses, leprosy, keloid, lupus vulgaris, or sarcoidosis \[[@pntd.0007698.ref033]\], a differential diagnosis can be very important for treatment. While microscopy and culture remain the gold standard for CL diagnosis, the sensitivity is variable and time consuming, demanding technical expertise and significant infrastructure. Serology-based method is not very useful in CL diagnosis because of undetectable or low antibodies titers. Many molecular diagnostic methods that allow the use of less invasive sampling with better sensitivity and specificity have been developed extensively for CL diagnosis. Particularly, PCR-technique targeting different gene sequences have been employed over the last decades for CL diagnosis \[[@pntd.0007698.ref034], [@pntd.0007698.ref035]\]. PCR platforms for CL show specificity (84%--100%) and sensitivity (90%--98%) \[[@pntd.0007698.ref034], [@pntd.0007698.ref036]\].

The first LAMP test for CL on skin biopsy was a generic, reverse transcriptase (RT-LAMP), targeting the conserved region of the *Leishmania* 18S ribosomal RNA (rRNA) gene with infection detection limit of 10 and 100 parasites/ml \[[@pntd.0007698.ref037]\]. Different studies have recently developed this technique for various applications, especially those based on the *Leishmania* 18S rRNA and minicircle kinetoplast DNA (kDNA) genes in CL endemic countries ([Table 1](#pntd.0007698.t001){ref-type="table"}). The choice of 18S rRNA gene in most pan-*Leishmania* LAMP assays was due to its high conservation across *Leishmania* species, while the kDNA gene has been proven to yield high sensitivity against other genes in comparative studies due to its high copy number \[[@pntd.0007698.ref038], [@pntd.0007698.ref039]\]. More recently, a LAMP assay targeting the cysteine protease B (cpb) gene has also been used for diagnosis of CL cases in Tunisia \[[@pntd.0007698.ref040]\]. A comparative study of pan-*Leishmania* LAMP assays employing primers targeting *Leishmania* 18S rRNA and histone genes, respectively, using purified DNAs of CL-causing species---*L*. (*L*.) *major*, *L*. (*L*.) *tropica*, *L*. (*L*.) *mexicana*, *L*. (*V*.) *braziliensis*, *L*. (*V*.) *guyanensis*, *L*. (*V*.) *panamensis*---revealed a similar limit of detection at 0.01 parasite/μl for both genes, but the histone primer was found to be incapable of amplifying all *L*. (*V*.) *guyanensis* and *L*. (*V*.) *braziliensis* strains tested, indicating low sequence homology to some strains \[[@pntd.0007698.ref039]\]. Studies have shown the usefulness of patient saliva \[[@pntd.0007698.ref041]\] and a direct boil-LAMP method \[[@pntd.0007698.ref042]\] in the diagnosis of CL. The boil method was found not to compromise *Leishmania* detection sensitivity of the LAMP assays \[[@pntd.0007698.ref042], [@pntd.0007698.ref043]\]. Furthermore, a Flinders Technology Associates (FTA)-LAMP for CL with detection sensitivity as low as 0.01 parasites/μl was demonstrated with clinical tissue spotted on FTA cards obtained from patients in Peru \[[@pntd.0007698.ref009]\]. The established LAMP assay showed the usefulness of FTA cards as a direct sampling tool for diagnosis of CL and was comparable to using purified DNA as a template. The reported FTA-LAMP is a further improvement in the application of LAMP in that it circumvents the need for liquid handling during sample collection and transportation, as well as refrigerant/cold storage. In spite of the fact that only a few human CL-LAMP studies were identified in our review of available literature, the diagnostic accuracy of LAMP testing for CL revealed sensitivity of 80%--92% and specificity of 94%--100% on tissue biopsies in three studies \[[@pntd.0007698.ref044]--[@pntd.0007698.ref046]\] ([Fig 3A](#pntd.0007698.g003){ref-type="fig"}). Overall, these reports support a potential role of LAMP as a reliable point-of-care (POC) diagnostic test for CL, which will be widely applicable in both endemic and nonendemic regions.

10.1371/journal.pntd.0007698.t001

###### Overview of LAMP assays for diagnosis of human and canine leishmaniases reported in previous studies.

![](pntd.0007698.t001){#pntd.0007698.t001g}

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Subject   LAMP target    Sample (n)                     DNA extraction                       Sensitivity\   Specificity\   Reference test    Dis.    Country                  Ref.
                                                                                               (%)            (%)                                                               
  --------- -------------- ------------------------------ ------------------------------------ -------------- -------------- ----------------- ------- ------------------------ ---------------------------------
  Human     kDNA           Blood (10)                     Qiagen Mini prep                     80.0           100            Microscopy        VL      Bangladesh               Takagi\
                                                                                                                                                                                and colleagues 2009\
                                                                                                                                                                                \[[@pntd.0007698.ref014]\]

  Human     I8S rRNA       Blood\                         Organic solvent                      83.0\          98.0\          Microscopy\       VL\     Sudan\                   Adams\
                           (30)\                                                               98.0           N/A            qRT-PCR           CL      Suriname                 and colleagues 2010\
                           Skin biopsy\                                                                                                                                         \[[@pntd.0007698.ref037]\]
                           (43)                                                                                                                                                 

  Human     kDNA           Buffy- coat (75)               Qiagen Mini prep                     90.7           100            Microscopy        VL      Bangladesh               Khan\
                                                                                                                                                                                and colleagues 2012\
                                                                                                                                                                                \[[@pntd.0007698.ref056]\]

  Human     kDNA           Blood (55)\                    Qiagen Mini prep                     96.4\          98.5\          Microscopy qPCR   VL\     India                    Verma\
                           BMA (15)\                                                           100\           98.5\                            VL\                              and colleagues 2013\
                           Tissue biopsy (62)                                                  96.8           100                              PKDL                             \[[@pntd.0007698.ref057]\]

  Dog       cpb            Blood (75)                     Wizard DNA kit                       54.2           80.0           Microscopy        CanL    Tunisia                  Chaouch\
                                                                                                                                                                                and colleagues 2013\
                                                                                                                                                                                \[[@pntd.0007698.ref072]\]

  Human     kDNA           Blood (47)                     Qiagen Mini prep                     93.6           100            DAT               VL      Iran                     Ghasemian\
                                                                                                                                                                                and colleagues 2014\
                                                                                                                                                                                \[[@pntd.0007698.ref059]\]

  Human     18S rRNA       Blood (2)\                     Direct-Boil\                         N/A            N/A            Microscopy        VL\     Thailand                 Sirworarat\
                           Saliva (2)\                    Qiagen Mini prep                                                                     CL\                              and colleagues 2015\
                           Tissue biopsy (1)\                                                                                                  CL\                              \[[@pntd.0007698.ref041]\]
                           BMA (1)                                                                                                             VL                               

  Dog       kDNA           Conjunct-\                     Boil-Spin                            61.3           97.0           Microscopy        CanL    China                    Gao and colleagues\
                           Ional\                                                                                                                                               2015 \[[@pntd.0007698.ref073]\]
                           swab (111)                                                                                                                                           

  Human     kDNA           Tissue biopsies\               Qiagen Mini prep                     82.6           100            Microscopy        CL      Sri Lanka                Kathalawala\
                           (31)                                                                                                                                                 &\
                                                                                                                                                                                Karunaweer,\
                                                                                                                                                                                2015 \[[@pntd.0007698.ref045]\]

  Human     18S rRNA       Tissue biopsy-FTA-card (122)   FTA purification reagent (Whatman)   N/A            N/A            Nested-PCR        CL      Peru                     Nzelu\
                                                                                                                                                                                and colleagues 2016\
                                                                                                                                                                                \[[@pntd.0007698.ref009]\]

  Human     kDNA           Blood (66)\                    Qiagen Mini prep                     96.9\          100\           qPCR              VL\     India                    Verma\
                           BMA (15)\                                                           100\           100\                             VL\                              and colleagues 2017\
                           Tissue biopsy (67)\                                                 97.0\          100\                             PKDL\                            \[[@pntd.0007698.ref044]\]
                           Tissue biopsy (10)                                                  80.0           100                              CL                               

  Human     18S rRNAand\   Whole blood and\               Boil-Spin and\                       97.6\          99.0\          Microscopy        VL      Sudan                    Mukhtar\
            kDNA           Buffy-coat (185)               Qiagen Mini prep                     100            99.0                                                              and colleagues 2018\
                                                                                                                                                                                \[[@pntd.0007698.ref020]\]

  Human     18S rRNA       Tissue biopsy (2)              Direct-Boil                          N/A            N/A            PCR               CL      Japan (Imported cases)   Imai\
                                                                                                                                                                                and colleagues 2018\
                                                                                                                                                                                \[[@pntd.0007698.ref042]\]

  Human     18S rRNAand\   Tissue biopsies (105)\         Qiagen Mini prep                     95.0\          86.0\          Microscopy        CL\     Colombia\                Adams\
            kDNA           Whole blood\                                                        92.3\          100\                             VL\     Ethiopia                 and colleagues 2018\
                           PBMC Buffy-coat (50)                                                88.5\          95.8\                            VL\                              \[[@pntd.0007698.ref039]\]
                                                                                               92.3           95.8                             VL                               

  Human     18S rRNAand\   Tissue biopsy\                 Qiagen Mini prep                     92.2           94.1           Microscopy\       CL      Afghanistan              Vink et al. 2018\
            kDNA           (274)                                                                                             PCR                                                \[[@pntd.0007698.ref046]\]

  Human     kDNA           Blood (179)\                   Qiagen Mini prep\                    98.3\          96.6\          Microscopy\       VL\     India                    Dixit and colleagues\
                           Blood (72)                     Direct-blood-lysis                   93.1           100            rK39\             VL                               2018 \[[@pntd.0007698.ref058]\]
                                                                                                                             qPCR                                               
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

BMA, bone marrow aspirates; CanL, canine leishmaniasis; CL, cutaneous leishmaniasis; cpb, cysteine protease B; DAT, direct agglutination test; Dis, disease; FTA, Flinders Technology Associates; kDNA, kinetoplast DNA; LAMP, loop-mediated isothermal amplification; n, number of samples; N/A, not applicable; PBMC, peripheral blood mononuclear cells; PKDL, post kala-azar dermal leishmaniasis; qPCR, quantitative PCR; qRT-PCR, quantitative reverse-transcriptase polymerase chain reaction; Ref, references; rK39, recombinant antigen-based immunochromatography test; VL, visceral leishmaniasis

![Reported LAMP diagnostic accuracy by study and test with forest plots.\
(A) Cutaneous leishmaniasis (CL)-LAMP on tissue biopsy (B) Visceral leishmaniasis (VL)-LAMP on whole blood. (C) VL-LAMP on buffy coat. (D) HIV-VL co-infection-LAMP on whole blood. (E) Post kala-azar dermal leishmaniasis (PKDL)-LAMP on tissue biopsy. FN, False-negative; FP, False-positive; TN: True-negative; TP, True-positive.](pntd.0007698.g003){#pntd.0007698.g003}

VL and PKDL {#sec006}
-----------

VL is characterized by fever, weight loss, wasting, and splenomegaly and is fatal if left untreated. VL is caused by *L*. (*L*.) *infantum* (both in the New and Old World) or *L*. (*L*.) *donovani* (only in the Old World). The disease is prevalent in tropical regions, with more than 90% of total cases reported from India, Bangladesh, Sudan, Brazil, Ethiopia, and South Sudan \[[@pntd.0007698.ref047]\]. Post kala-azar dermal leishmaniasis (PKDL) is a complication of VL, characterized by macular, maculopapular, and nodular lesions in a patient who has recovered from VL. Significantly, during interepidemic periods of VL, patients who developed PKDL are considered as potential reservoir hosts for the parasite \[[@pntd.0007698.ref048]\]. Therefore, detection and identification of both VL and PKDL patients in endemic areas are of paramount importance to combat leishmaniasis.

Diagnosis of both VL and PKDL relies on microscopic examination of tissue smears; however, this method suffers from low sensitivity. For VL, microscopy has a sensitivity of 93%--99% for spleen aspirate, 53%--86% for bone marrow, and 53%--65% for lymph node aspirates \[[@pntd.0007698.ref049]\], while for PKDL it has a sensitivity of 67%--100% for nodular lesions, 36%--69% for popular lesions, and 7%--33% for macular lesions \[[@pntd.0007698.ref050]\]. Serological methods such as DAT, ELISA, and the rK39 strip test have high sensitivity but come with their own challenges---like an inability to discriminate between symptomatic and asymptomatic cases, cross-reactivity with other diseases, and inconsistent performance in HIV-VL co-infection cases---and are particularly not conclusive for PKDL diagnosis \[[@pntd.0007698.ref051]--[@pntd.0007698.ref052]\]. Like in the case of CL diagnosis, several PCR molecular-based tools have been successfully shown to have increased sensitivity and accuracy in VL and PKDL diagnosis using various templates \[[@pntd.0007698.ref006], [@pntd.0007698.ref035], [@pntd.0007698.ref053]\]. Molecular tests are potentially important in the case of HIV-VL co-infection because of low antibody response in HIV-infected patients, which lowers the sensitivity of serological tests \[[@pntd.0007698.ref054]\]. Among the three forms of leishmaniasis, the development of diagnostics for VL based on LAMP has gained more focus, and the Foundation for Innovative New Diagnostics (FIND) has also devoted its efforts towards reducing the burden of VL through innovative LAMP technique (<http://www.finddiagnostics.org>). Such interest on VL is not surprising because recent VL diagnostics modelling data indicate that early diagnosis and treatment of patients have the potential to immensely reduce the transmission of the disease in endemic areas \[[@pntd.0007698.ref055]\]. Therefore, early detection of the infectious agent will require a simple and rapid specific test, which consequently makes LAMP an ideal test for VL.

Species-specific LAMP assays based on the kDNA gene have been largely established for VL and PKDL diagnosis in endemic areas ([Table 1](#pntd.0007698.t001){ref-type="table"}), as well as genus-specific LAMP for VL either based on the *Leishmania* 18S rRNA or ITS1 genes \[[@pntd.0007698.ref028], [@pntd.0007698.ref041]\], which were in-house assays. Loopamp *Leishmania* Detection kit (Eiken Chemical, Japan), a first *Leishmania* LAMP kit, which comes in a ready-to-use format with primers targeting both 18S rRNA and kDNA minicircles, specific to the *Leishmania* genus has also been evaluated for the diagnosis of VL \[[@pntd.0007698.ref020]\]. There were no significant differences between the sensitivities or specificities of the LAMP kit test on whole blood and buffy-coat samples processed either by the simple boil and spin method or commercial QIAgen kits for VL in Sudan \[[@pntd.0007698.ref020]\]. A similar study has shown that LAMP performed on DNA extracted from whole blood had good sensitivity compared to microscopy of highly invasive biopsy samples \[[@pntd.0007698.ref039]\]. The diagnostic accuracy of LAMP testing for VL was reported as high (sensitivity 80%--100% and specificity 96%--100%) in all studies irrespective of the sample tested (whole blood, buffy coat) \[[@pntd.0007698.ref014], [@pntd.0007698.ref020], [@pntd.0007698.ref037], [@pntd.0007698.ref039], [@pntd.0007698.ref044], [@pntd.0007698.ref056]--[@pntd.0007698.ref059]\] ([Fig 3B and 3C](#pntd.0007698.g003){ref-type="fig"}). The amplification efficiency of LAMP in detection of *Leishmania* infection in multiple less or noninvasive DNA sources, such as saliva and peripheral blood \[[@pntd.0007698.ref041]\], is valuable in reducing the probability of a false negative. In addition, LAMP may particularly be important for patients who are co-infected with human immunodeficiency virus (HIV). In patients suffering from both HIV and VL, LAMP was proven to have a good diagnostic efficacy with 100% (95% CI, 59%--100%) sensitivity and 100% (95% CI, 86%--100%) specificity \[[@pntd.0007698.ref039], [@pntd.0007698.ref041]\] ([Fig 3D](#pntd.0007698.g003){ref-type="fig"}). Two studies provided diagnostic accuracy on LAMP testing for PKDL on tissue biopsies \[[@pntd.0007698.ref044], [@pntd.0007698.ref057]\]. The sensitivity and specificity were reported as high (97% and 100%, respectively) in both studies ([Fig 3E](#pntd.0007698.g003){ref-type="fig"}). Furthermore, at VL and PKDL posttreatment stages, LAMP can potentially be utilized in the assessment of cure \[[@pntd.0007698.ref044]\]; however, a study had previously revealed the inability of LAMP to amplify posttreatment patients when the number of parasites fell to extremely low levels, approximately 10 parasites/ml \[[@pntd.0007698.ref037]\]. Variation in the LAMP detection limit or sensitivity may be related to the primers and the target region selected, the *Leishmania* species involved, and the DNA extraction methods employed. Taken collectively, LAMP has shown very good diagnostic performance for VL and PKDL---with high sensitivity and specificity similar to PCR methods---and has emerged as a promising POC test for screening at-risk populations, and HIV-VL diagnosis, as well as assessment of cure for VL and PKDL in endemic areas.

Canine leishmaniasis (CanL) {#sec007}
---------------------------

Canine leishmaniasis (CanL) is an important zoonotic disease mainly caused by *L*. (*L*.) *infantum*, which is associated with the long history of companionship between dogs and humans, as well as with sand fly vectors. The disease exists in about 50 countries among the 98 countries where human leishmaniases are endemic, affecting mainly three foci: China, the Mediterranean basin, and Brazil \[[@pntd.0007698.ref060]\]. Although *L*. (*L*.) *infantum* has been identified as the main aetiologic agent of CanL in the Old World \[[@pntd.0007698.ref061]\], in the New World other species such as *L*. (*L*.) *chagasi* (*infantum*), *L*. (*L*.) *mexicana*, *L*. (*L*.) *amazonensis*, and *L*. (*V*.) *braziliensis* may be included as potential aetiologic agents \[[@pntd.0007698.ref060], [@pntd.0007698.ref062]\]. Canine infection with *Leishmania* has two effects: as a reservoir for human leishmaniasis and as a cause of a severe disease in dogs, which is usually fatal when left untreated \[[@pntd.0007698.ref063]\]. Infected dogs play an important role in the transmission of leishmaniasis and as such represent a real threat to uninfected dogs and humans in endemic areas where sand fly vectors are present. Symptomatic dogs present clinical signs such as peripheral lymphadenopathy, weight loss, papular, nodular dermatitis, decreased appetite, lethargy, and splenomegaly \[[@pntd.0007698.ref060], [@pntd.0007698.ref064]\]. The diagnosis of CanL is complex due to its variable clinical manifestations and lack of symptoms during the early stage of the infection. Therefore, a reliable, accurate, and rapid diagnostic test is essential in early management of infected dogs and to prevent zoonotic transmission of the *Leishmania* parasite to humans in endemic areas. CanL diagnosis does not differ substantially from that in humans; several direct methods (culture of parasites and microscopy) and indirect methods (serological and molecular tests) are readily available for the diagnosis of CanL.

Parasitological and serological tests have limitations in the diagnosis of CanL, especially in asymptomatic dogs or during early infection \[[@pntd.0007698.ref065]\]. Although parasitological diagnosis is the definitive methodology of detection and splenic aspirates are considered as the method of choice among lymph node and bone marrow for CanL diagnosis \[[@pntd.0007698.ref066]\], CanL is frequently diagnosed through the detection of specific antibodies against *Leishmania* parasites, using serological techniques. However, serological tests (DAT, IFAT, ELISA) present some draw backs, such as cross-reaction with *Trypanosoma* parasites, species causing CL, and other hemoparasites; and false results in low titers or cases of immunological anergy \[[@pntd.0007698.ref067]\]. Nevertheless, PCR with all its variants has had the greatest success due to its high sensitivity (89% to 100%) and specificity (95% to 100%) in the diagnosis of CanL \[[@pntd.0007698.ref068]--[@pntd.0007698.ref071]\].

Few studies have shown the utility of LAMP in the diagnosis of CanL ([Table 1](#pntd.0007698.t001){ref-type="table"}). A *L*. (*L*.) *infantum*-specific LAMP assay was developed successfully, targeting the cpb multicopy gene to detect parasites in the blood of 75 dogs using purified DNA \[[@pntd.0007698.ref072]\]. The LAMP delivered 54.2% sensitivity and 80% specificity, and the results were comparable with nested-PCR but had lower sensitivity to IFAT (88.5%), which showed in contrast lower specificity (45%) \[[@pntd.0007698.ref072]\]. A further study compared the performance of kDNA-based *L*. (*L*.) *infantum*-specific LAMP assay on conjunctival swab samples with conventional PCR, ELISA (serum), and microscopy (bone marrow) and found that LAMP detected 61.3% of infected dogs, which was similar to PCR (58.6%) and significantly higher than ELISA (40.5%) and microscopy (10.8%) \[[@pntd.0007698.ref073]\]. However, the kDNA LAMP primer sets designed from a *L*. (*L*.) *infantum* strain isolated in China did not amplify strains from other countries and as such are not suitable for use in other endemic areas. Additionally, the study highlighted that the noninvasive sample collection resulted in a high uptake among dog owners, which is commendable for the control of CanL. These studies provide examples of how LAMP can be implemented in field detection and early management of CanL.

Molecular xenomonitoring/surveillance potentials of LAMP for leishmaniasis {#sec008}
==========================================================================

Molecular xenomonitoring (MX) is the screening of haematophagous insects for the presence of a pathogen's genetic material (DNA/RNA) using molecular-based assays. Phlebotomine sand flies are the putative vectors of leishmaniases, and approximately 800 species have been recorded in five major genera: *Phlebotomus* and *Sergentomyia* in the Old World and *Lutzomyia*, *Brumptomyia*, and *Warileya* in the New World \[[@pntd.0007698.ref074]\]. However, only species belonging to the genera *Phlebotomus* and *Lutzomyia* are the putative vectors of *Leishmania* \[[@pntd.0007698.ref074], [@pntd.0007698.ref075]\]. The spread of leishmaniasis largely depends on the distribution of sand fly vectors. Therefore, entomological monitoring of *Leishmania* infection in leishmaniasis endemic areas provides epidemiologic advantages for predicting the risk and expansion of the diseases, the estimation of which depends on the reliable identification of infected sand flies \[[@pntd.0007698.ref027]\]. Additionally, estimation of infection rates in the vector could serve as an indicator of a change in transmission intensity and assessment of control programs \[[@pntd.0007698.ref027]\].

Hitherto, detection of *Leishmania* parasites within individual sand flies relied largely on dissection and microscopic examination of individual flies, which is technically demanding, laborious, and time consuming---especially when large numbers of specimens must be examined due to the low *Leishmania* infection rate in sand flies (0.01%--1%), even in endemic areas \[[@pntd.0007698.ref076]\]. To overcome these technical limitations, in the last three decades molecular approaches (PCR formats) have been increasingly employed in the detection of *Leishmania* DNA in individual or pooled sand flies \[[@pntd.0007698.ref076], [@pntd.0007698.ref077]\]. Of interest, LAMP has also been shown to be a good MX tool for generation of information on the distribution or expansion of leishmaniasis. In addition, from cost-effectiveness and field perspectives, LAMP offers some advantages over PCR as a usefulness method for surveillance and epidemiological studies of leishmaniasis in endemic areas. The first established LAMP for rapid mass-screening of individual sand flies for *Leishmania* infection was a generic-*Leishmania* 18S rRNA-based LAMP with preaddition of malachite green (MG) detection closed system, which can detect 0.01 parasites \[[@pntd.0007698.ref027]\]. The field-based-MG-LAMP results using a crude sand fly template without DNA purification for *Leishmania* DNA detection ([Fig 4](#pntd.0007698.g004){ref-type="fig"}) were comparable to classical microscopy and PCR. The LAMP was found to be a high-throughput screening tool for the detection of *Leishmania*-infected *Lutzomyia* sand fly species (8 out of 397 field-caught flies) in the endemic areas of Ecuador \[[@pntd.0007698.ref027]\]. Another study validated the established LAMP for individual screening of 150 wild-caught sand flies from endemic areas of Iran and revealed that the 18S rRNA-based-LAMP detected 10 *Leishmania* DNA positive sand flies (*Sergentomyia baghdadis*, *S*. *sintoni*, and *Phlebotomus papatasi*) \[[@pntd.0007698.ref078]\]. A similar study also experimentally validated the potential field applicability of the MG-LAMP for detection of *L*. *martiniquensis* DNA in sand flies in Thailand; however, no *Leishmania* DNA was detected by LAMP and PCR when applied to 380 field-caught flies, probably due to low infection rate in the study area \[[@pntd.0007698.ref079]\]. Additionally, the performance of the MG-LAMP was further validated using purified DNA from sand fly pools and was found to be of potential use for the entomological surveillance of CL in Colombia with 100% sensitivity and 96.8% specificity \[[@pntd.0007698.ref080]\]. Indeed, these reported studies have shown the potential usefulness of LAMP for mass-screening of sand flies in the Old and New World. Importantly, LAMP allows for an immediate real-time assessment of the presence of *Leishmania* parasites in endemic foci, which demonstrates the possibility of its integration as a simple and cost-effective molecular tool for monitoring or surveillance of infections and identification of the vector species.

![Graphic demonstration of colorimetric-MG-based LAMP assay for rapid mass-screening of individual sand flies for *Leishmania* infection.](pntd.0007698.g004){#pntd.0007698.g004}

LAMP amplicon end-point closed detection system {#sec009}
===============================================

A wide range of approaches are available for the qualitative detection of LAMP amplicons. The amplified products can be detected visually using multiple parameters, including turbidity, fluorescence, and color with the naked eyes and/or UV light ([Table 2](#pntd.0007698.t002){ref-type="table"}). Following agarose gel electrophoresis, an open detection system is usually used as a confirmatory analysis of the LAMP products that appear as cauliflower-like structures with multiple loops. The presence of turbidity (white color precipitate) in sample from byproducts of amplification has been used as the indicator of a positive *Leishmania* DNA LAMP reaction, while absence of turbidity indicated a negative LAMP reaction \[[@pntd.0007698.ref043], [@pntd.0007698.ref056]\]. However, turbidity is challenging to discern and is unstable over time. As an alternative to turbidity, intercalating fluorescent dyes were used for direct detection of the *Leishmania* DNA LAMP positive samples such as calcein \[[@pntd.0007698.ref073]\], SYBR Green I \[[@pntd.0007698.ref057], [@pntd.0007698.ref078]\], fluorescent detection reagents (FDR) (Eiken) \[[@pntd.0007698.ref037], [@pntd.0007698.ref043]\], which are technically inconvenient due to its requirement for a UV illuminator for test result discrimination, and can bind nonspecifically to any dsDNA, even to the primer-dimers leading to an incorrect interpretation of results \[[@pntd.0007698.ref081]\]. In addition, fluorescence-based assays require specialized equipment such as the LED illuminators \[[@pntd.0007698.ref021]\] to enable the readout of the fluorescence dyes or the use of real-time fluorimetry \[[@pntd.0007698.ref021], [@pntd.0007698.ref028]\]. The use of specialized equipment for the visualization of the LAMP results reduces the versatility of the LAMP and tends to increase the overall cost of the LAMP assay, which might hinder its use in resource-limited countries. On the other hand, despite the reported good sensitivity, SYBR Green I could inhibit the LAMP reaction if added before isothermal incubation. Therefore, the dye must be introduced post-LAMP reaction, requiring the LAMP tube to be opened or postamplification handling (open detection system), which is a contamination risk and usually leads to false-positive results. Recently, studies have shown the use of SYBR Green I placed on the inner side of the cap of reaction tube in a closed-LAMP assay; however, the assay requires an additional step of brief spin after LAMP reaction for amplicon discrimination \[[@pntd.0007698.ref044], [@pntd.0007698.ref058]\]. The detection of amplicon with preaddition of FDR eliminates the openings of tubes and reduces contamination problems; however, FDR has low detection sensitivity \[[@pntd.0007698.ref082]\] and is costly \[[@pntd.0007698.ref037]\]. Colorimetric-LAMP detection dyes, like hydroxy naphthol blue (HNB) and MG, have also been utilized for the naked eye visualization of positive LAMP products in closed systems. The addition of HNB and MG dyes in the LAMP reaction tube prior amplification eliminates the opening of tubes and completely avoids contamination problems \[[@pntd.0007698.ref009], [@pntd.0007698.ref027]\]. HNB dye changes from violet to a sky blue color \[[@pntd.0007698.ref082]\] and requires the operator to distinguish between positive and negative color results, which can be ambiguous. In contrast, MG signal recognition is highly sensitive, the system gives a clear-cut difference between positives (light blue color) and negatives (colorless) based on naked eye visualization, and interpretation by an independent observer is not required \[[@pntd.0007698.ref009], [@pntd.0007698.ref027], [@pntd.0007698.ref041], [@pntd.0007698.ref080]\]. MG-LAMP products are stable and thus can be kept for record purposes. Several studies have shown the reliability, robust sensitivity, and wide applicability of MG-based-LAMP closed detection system for *Leishmania* and other purposes. MG has been used for detection of *Leishmania* DNA in crude *Lutzomyia* sand fly extract in Ecuador \[[@pntd.0007698.ref027]\]; patient's tissue spotted on FTA-card in Peru \[[@pntd.0007698.ref009]\]; blood, saliva, and tissue biopsies in Thailand \[[@pntd.0007698.ref041]\]; and direct smears and sand flies in Colombia \[[@pntd.0007698.ref080]\]. Taken together, the incorporation of a closed-LAMP assay offer new prospects for improved detection of infections, as well as positioning LAMP as a quick, one-step, POC molecular diagnostic and xenomonitoring tool for leishmaniasis and other diseases.

10.1371/journal.pntd.0007698.t002

###### Summary of methods used in LAMP amplicon end-point detection in previous studies.

![](pntd.0007698.t002){#pntd.0007698.t002g}

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Detection parameter     Open/\           Evaluation of results    Equipment for end-point detection   Remarks                                                                                References
                          closed system                                                                                                                                                        
  ----------------------- ---------------- ------------------------ ----------------------------------- -------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Turbidity               Closed           Turbid---positive\       Turbidimeter or none                Not always easy to interpret                                                           Khan and colleagues 2012 \[[@pntd.0007698.ref056]\]; Mikita\
                                           Clear---negative                                                                                                                                    and colleagues 2014 \[[@pntd.0007698.ref043]\]

  Gel-electrophoresis     Open             Ladder-like\             UV transilluminator                 Prone to contamination                                                                 Nzelu and colleagues 2014 \[[@pntd.0007698.ref027]\]; Gao and colleagues 2015 \[[@pntd.0007698.ref073]\]
                                           bands---positive\                                                                                                                                   
                                           No band---negative                                                                                                                                  

  Calcein                 Closed           Green---positive\        UV lamp                             Inconvenient due to dangerous UV illuminator                                           Gao and colleagues 2015 \[[@pntd.0007698.ref073]\]
                                           Orange---negative                                                                                                                                   

  SYBR Green I            Open or closed   Green---positive\        UV light or none                    Inhibits LAMP reaction and prone to contamination when added postreaction              Verma and colleagues 2013, 2017 \[[@pntd.0007698.ref044], [@pntd.0007698.ref057]\]; Ghodrati and colleagues 2017 \[[@pntd.0007698.ref078]\]; Dixit and colleagues 2018 \[[@pntd.0007698.ref058]\]
                                           Orange---negative                                                                                                                                   

  FDR (Eiken)             Closed           Fluorescent\             UV light                            Expensive                                                                              Adams\
                                           green---positive\                                                                                                                                   and colleagues 2010 \[[@pntd.0007698.ref037]\]; Mikita\
                                           Pale brown---negative                                                                                                                               and colleagues 2014 \[[@pntd.0007698.ref043]\]

  Hydroxy naphthol blue   Closed           Sky blue---positive\     Light box (optional) or none        Ambiguous to discern, requires operator to distinguish results                         Goto and colleagues 2009 \[[@pntd.0007698.ref082]\]
                                           Violet---negative                                                                                                                                   

  Malachite green         Closed           Light blue---positive\   None                                Easy to discern results by the naked eye; stable and can be kept for record purposes   Nzelu and colleagues 2014 \[[@pntd.0007698.ref027]\], 2016 \[[@pntd.0007698.ref009]\]; Sriworarat and colleagues 2015 \[[@pntd.0007698.ref041]\]; León and colleagues 2018 \[[@pntd.0007698.ref080]\]
                                           Colorless---negative                                                                                                                                
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

FDR, Fluorescent detection reagent; LAMP, loop-mediated isothermal amplification: UV, ultra-violet

Cost and hands-on time of the *Leishmania* LAMP test {#sec010}
====================================================

Besides technical feasibility and performance, the major issue related to the large-scale and routine implementation of molecular diagnostics is its cost-effectiveness. LAMP has proven to be applicable to field detection, potentially eliminating the need for expensive DNA purification kits, thermal cyclers, and gel electrophoresis. The reported costs of *Leishmania* LAMP range from less than US\$1--\$3.50 per test \[[@pntd.0007698.ref037], [@pntd.0007698.ref043]\], compared to US\$12 for qPCR, US\$2.50 for PCR-restriction fragment length polymorphism (PCR-RFLP) \[[@pntd.0007698.ref034], [@pntd.0007698.ref037]\], US\$1.5--2.5 for DAT, around US\$1 for rk39-based immunochromatographic-RDT \[[@pntd.0007698.ref083]\], and less than US\$1 for microscopy per test. Some studies have suggested that the use of a very cheap colorimetric dye like MG \[[@pntd.0007698.ref009], [@pntd.0007698.ref080]\] for LAMP amplicon visualization, instead of Eiken fluorescent detection reagent \[[@pntd.0007698.ref037]\], and heat treated samples as a template DNA source \[[@pntd.0007698.ref041]--[@pntd.0007698.ref043], [@pntd.0007698.ref058]\] may further reduce the cost per test. A study indicated that a malaria LAMP assay using heat treated blood cost between US\$0.40 and US\$0.70, which is lower than currently available RDT's \[[@pntd.0007698.ref013]\]. Although *Leishmania*-RDT has a cost similar to microscopy when used at reference centers/clinics, LAMP appears to be more appropriate and cost effective during CL seasons or outbreaks, when its capacity to process several tests at a time can be maximized \[[@pntd.0007698.ref084]\]. Moreover, lowering the cost of LAMP will broaden its application, especially in resources-limited countries where leishmaniasis is endemic.

Rapid turnaround time is equally an important aspect of any test, and patients and clinicians require a test that can produce a result rapidly for prompt treatment. The hands-on time to result for closed-LAMP is 30--60 mins \[[@pntd.0007698.ref009], [@pntd.0007698.ref020], [@pntd.0007698.ref044]\], compared to 3--6 hours for most PCR assays and 10--20 mins for rK39-RDT \[[@pntd.0007698.ref083]\]. LAMP, being much faster than PCR assays, falls in the category of a high performance result oriented NAAT, which will support leishmaniasis elimination initiatives.

Concluding remarks and future directions {#sec011}
========================================

The development and application of LAMP technique in the diagnosis of leishmaniasis cases in endemic areas is in line with the recent global trend in seeking rapid, POC tests for the control of infectious diseases. LAMP appears to be an ideal diagnostic test suitable for neglected and forgotten tropical diseases in the world, including leishmaniasis. Furthermore, it meets the guidelines laid down by the World Health Organization (WHO) that diagnostics for developing countries should be ASSURED: Affordable, Sensitive, Specific, User-friendly, Rapid and robust, Equipment-free, and Deliverable to end users \[[@pntd.0007698.ref085]\]. In this review, we compiled the diagnostic performance and recent advances employing the LAMP assay to detect *Leishmania* in human CL, VL, PKDL, CanL, and sand flies. Based on the current review and discussion, the following points should be considered. 1) Making diagnostic techniques patient-centric (in-clinic and in the field) was the main aim behind the advent of LAMP as a POC test; therefore, LAMP quantitative diagnostic methods that were developed are not applicable as POC tests because they require relatively costly equipment and personnel. Quantitative assays are good for special purposes, such as research. 2) The sensitivity and specificity of LAMP largely depends on the primer sets employed; hence, care must be taken when designing primers. Although it is challenging to choose a correct and proper target for amplification (either a highly conserved region or a target site that is species-specific), it is imperative to ensure that the assay amplifies the predicted target and is specific, which may require some preliminary experimental optimization before final primer selection. While the Primer Explorer software can be employed to design primer sets, successful primers can be manually designed even when preferred target sites are not selected by the software. 3) One of the most attractive features of LAMP is the ability to overcome potential inhibitors in unpurified templates. The use of boiled clinical samples \[[@pntd.0007698.ref041]--[@pntd.0007698.ref043]\], direct-blood lysis \[[@pntd.0007698.ref058]\], and crude sand fly extract \[[@pntd.0007698.ref027]\] reduces time, cost, and the requirement for extensive laboratory infrastructure. The stability of the target DNA in crude sand fly extract stored at −20°C for months/years has been reported \[[@pntd.0007698.ref027]\] but has not been reported for boiled supernatant (boil and spin or Direct Boil-LAMP). Hence, it is important to develop buffers that can stabilize DNA in the supernatant in order to ensure subsequent amplification consistency before it can be relied upon as template. 4) High risk of carry-over contamination, which often leads to false-positive results in supposedly negative controls, is a major challenge of LAMP. Amplicons are usually stable, and as such, unintended carry-over contamination may occur. It is recommended to adopt a closed end-point detection system in order to avoid postamplification contamination. 5) The Loopamp *Leishmania* Detection Kit---which is in a ready-to-use format, has an additional advantage of dried reagents including *Leishmania* genus-specific primers, and has shelf life of one year if stored between 1 and 30°C (Eiken)---is a further advancement of LAMP. Additionally, an electricity-free stable heat block based on exothermic chemical reactions and phase-change material has been demonstrated for amplification reaction \[[@pntd.0007698.ref086]\], and the use of rechargeable solar batteries as alternative energy-source has also been proposed \[[@pntd.0007698.ref081]\]. However, the development of a consensus standardized integrated system from simple sample collection and preservation, template preparation, and amplification platform to closed detection unit for end-point use will be essential for field and in-clinic testing even in the most remote rural endemic areas. 6) It is important to highlight that LAMP positivity should always be interpreted in combination with clinic pathological evaluations. Focusing on the aforementioned points will undoubtedly improve the application of LAMP in the diagnosis of leishmaniasis. Importantly, LAMP has come to stay as a potential rapid POC test for diagnosis and entomological monitoring of *Leishmania* infection in endemic areas.

Key Learning Points {#sec012}
-------------------

-   Leishmaniasis remains one of the world's most neglected and poverty-related tropical diseases, and early detection of *Leishmania* will require a simple and rapid diagnostic test for timely treatment of patients.

-   A closed LAMP diagnostic tool with high specificity, sensitivity, rapidity, and simplicity provides an effective point-of-care test applicable in *Leishmania* endemic and nonendemic areas.

-   LAMP tests are potentially important in the diagnosis of HIV-VL co-infection cases because of low antibody response in HIV-infected patients, which lowers the sensitivity of serological tests.

-   A rapid and reliable diagnostic test is important for the management of *Leishmania*-infected dogs to prevent zoonotic transmission of the parasite in endemic areas.

-   LAMP allows for an immediate real-time assessment of the presence of *Leishmania* parasites in endemic foci, and monitoring of *Leishmania* infection in sand flies can provide epidemiologic data for predicting the risk and expansion of the disease.
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